Table 4.
Comparison of the prevalence rate of PPO among the control and intervention groups
| Type of PPOs according to START criteria | Control Group N (%) | Intervention group N (%) |
|---|---|---|
| Cardiovascular System | ||
| “Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors in the presence of chronic atrial fibrillation” | 2 (0.8) | 7 (2.9) |
| “Antiplatelet therapy with a documented history of coronary, cerebral or peripheral vascular disease” | 10 (4.2) | 5 (2.1) |
| “Statin therapy with a documented history of coronary, cerebral or peripheral vascular disease” | 11 (4.6) | 11 (4.6) |
| “Angiotensin Converting Enzyme (ACE) inhibitor with systolic heart failure and/or documented coronary artery disease” | 30 (12.5)* | 16 (6.7)* |
| “Beta-blocker with ischaemic heart disease” | 22 (9.2) | 16 (6.7) |
| “Appropriate beta-blocker (bisoprolol, nebivolol, metoprolol or carvedilol) with stable systolic heart failure” | 6 (2.5) | 6 (2.5) |
| Respiratory System | ||
| “Regular inhaled ß2 agonist or antimuscarinic bronchodilator mild to moderate asthma or COPD” | 11 (4.6) | 17 (7.1) |
| “Regular inhaled corticosteroid for moderate-severe asthma or COPD” | 10 (4.2) | 6 (2.5) |
| Musculoskeletal System | ||
| “Vitamin D supplements in older people who are housebound or experiencing falls or with osteopenia” | 37 (15.4)** | 14 (5.8)** |
| “Xanthine-oxidase inhibitors with a history of recurrent episodes of gout” | 2 (0.8) | 3 (1.3) |
| Endocrine System | ||
| “ACE inhibitor or Angiotensin Receptor Blocker (if intolerant of ACE inhibitor) in diabetes with evidence of renal disease” | 20 (8.3) | 29 (12.1) |
| Urogenital System | ||
| “Alpha-1 receptor blocker with symptomatic prostatism, where prostatectomy is not considered necessary” | 9 (3.8) | 6 (2.5) |
| “5-alpha-reductase inhibitor with symptomatic prostatism, where prostatectomy is not considered necessary” | 12 (5.0) | 9 (3.8) |
COPD chronic obstructive pulmonary disease.
*p = 0.03; **p = 0.001